These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 2830532)

  • 1. Pharmacological evaluation of agonistic and antagonistic activity of cannabinoids.
    Martin BR; Compton DR; Little PJ; Martin TJ; Beardsley PM
    NIDA Res Monogr; 1987; 79():108-22. PubMed ID: 2830532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular effects of cannabinoids.
    Martin BR
    Pharmacol Rev; 1986 Mar; 38(1):45-74. PubMed ID: 2872689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis: pharmacology and toxicology in animals and humans.
    Adams IB; Martin BR
    Addiction; 1996 Nov; 91(11):1585-614. PubMed ID: 8972919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.
    Melvin LS; Milne GM; Johnson MR; Subramaniam B; Wilken GH; Howlett AC
    Mol Pharmacol; 1993 Nov; 44(5):1008-15. PubMed ID: 8246904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid pharmacology.
    Dewey WL
    Pharmacol Rev; 1986 Jun; 38(2):151-78. PubMed ID: 3529128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.
    Little PJ; Compton DR; Johnson MR; Melvin LS; Martin BR
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1046-51. PubMed ID: 2849657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The functional neuroanatomy of brain cannabinoid receptors.
    Breivogel CS; Childers SR
    Neurobiol Dis; 1998 Dec; 5(6 Pt B):417-31. PubMed ID: 9974175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the cannabinoid receptor: a three-dimensional quantitative structure-activity analysis.
    Thomas BF; Compton DR; Martin BR; Semus SF
    Mol Pharmacol; 1991 Nov; 40(5):656-65. PubMed ID: 1944237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol.
    Beardsley PM; Scimeca JA; Martin BR
    J Pharmacol Exp Ther; 1987 May; 241(2):521-6. PubMed ID: 3033218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptors in atherosclerosis.
    Steffens S; Mach F
    Curr Opin Lipidol; 2006 Oct; 17(5):519-26. PubMed ID: 16960500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency.
    Thomas BF; Compton DR; Martin BR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):624-30. PubMed ID: 2173751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoids, endogenous ligands and synthetic analogs.
    Pop E
    Curr Opin Chem Biol; 1999 Aug; 3(4):418-25. PubMed ID: 10419842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids.
    Lynn AB; Herkenham M
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1612-23. PubMed ID: 8138973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
    Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
    Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.
    McCarberg BH; Barkin RL
    Am J Ther; 2007; 14(5):475-83. PubMed ID: 17890938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs.
    Hayase T
    BMC Neurosci; 2007 Sep; 8():76. PubMed ID: 17877812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids: the separation of central from peripheral effects on a structural basis.
    Evans FJ
    Planta Med; 1991 Oct; 57(7):S60-7. PubMed ID: 1659702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical effects: learned behavior.
    Ferraro DP
    NIDA Res Monogr; 1977 Jul; (14):103-17. PubMed ID: 411038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.